Prehabilitation to Patients With Prostate Cancer
NCT07162987
Summary
The goal of this feasibility study is to test a newly developed, multicomponent prehabilitation intervention to patients with prostate cancer, to improve their resilience to treatment side-effects. The main questions it aims to answer are: * Are patients and their close relatives willing to take part in prehabilitation? * What is the acceptability and feasibility of the prehabilitation intervention, seen from the perspectives of patients, their close relatives, and healthcare professionals? * Are the planned data collection methods feasible, and are there indications of a clinical effect? Participants will: * Take part in 12 weeks of physical exercise training * Attend a 4-day residential prehabilitation intervention, where they receive education and do exercises. After 12 weeks, it is possible to take part in a voluntary follow-up session. * Patients will respond to questionnaires about their health, symptoms, and quality of life. Patients and their close relatives will attend a group interview. Patients will also complete an exercise diary and brief physical tests
Eligibility
Inclusion Criteria: * Diagnosed with prostate cancer * min 18 years old * Treatment: Androgen deprivation therapy and raditation therapy * Resident in Vejle Municipality or Esbjerg Municipality * Can take part in residential prehabiliation in week 43 or 50, 2025, as well as physical exsercise training in the municipality * Willing to take part in a research study * Suited to take part in group sessions * Be able to read and be understood in Danish * Be responsible for own personal hygiene and medications at the 4-day residential stay Exclusion Criteria: * Persons who do not fulfil the inclusion criteria will be excluded
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07162987